Are you over 18 and want to see adult content?
More Annotations
A complete backup of https://builtwith.com/hcccontinuinged.com
Are you over 18 and want to see adult content?
A complete backup of https://ura99.com/category/digi-tents/page/653/
Are you over 18 and want to see adult content?
A complete backup of https://minify.mobi/results/ibto.ir
Are you over 18 and want to see adult content?
A complete backup of https://debsbluetongueskinks.weebly.com/
Are you over 18 and want to see adult content?
A complete backup of https://www.shoprite.com/
Are you over 18 and want to see adult content?
A complete backup of https://www.bmi.ir/news/news/details/16620
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of https://larousse.com
Are you over 18 and want to see adult content?
A complete backup of https://gamesbras.com
Are you over 18 and want to see adult content?
A complete backup of https://chromehearts.net.co
Are you over 18 and want to see adult content?
A complete backup of https://magic-help.com.ua
Are you over 18 and want to see adult content?
A complete backup of https://thedepauw.com
Are you over 18 and want to see adult content?
A complete backup of https://uscj.org
Are you over 18 and want to see adult content?
A complete backup of https://htmlka.com
Are you over 18 and want to see adult content?
A complete backup of https://museumsbund.de
Are you over 18 and want to see adult content?
A complete backup of https://hydroshare.org
Are you over 18 and want to see adult content?
A complete backup of https://boycrush.com
Are you over 18 and want to see adult content?
A complete backup of https://gulfcoastjam.com
Are you over 18 and want to see adult content?
Text
database.
REQUEST | PSYCHIATRIST.COM Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be THE MINI-INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW (M.I.N.I J Clin Psychiatry 1998;59 (suppl 20) 23 Development and Validation of the M.I.N.I. © Copyright 1998 Physicians Postgraduate Press, Inc. One personal copy may be printed PREVALENCE, IMPACT, AND BURDEN OF INSOMNIA AND DISCUSSING Prevalence, Impact, and Burden of Insomnia and Discussing It With Patients. Russell P. Rosenberg, PhD. Insomnia is the most prevalent sleep-wake disorder, with about one in ten individuals meeting diagnostic criteria. Associated with significant impairment in daytime function, insomnia has a vast societal burden and impact on publichealth.
TREATING GENERALIZED ANXIETY DISORDER WITH COGNITIVE Treating Generalized Anxiety Disorder With Cognitive 14 cbt. EFFECTIVENESS OF ANTIDEPRESSANTS: COMPARATIVE REMISSION RATES Effectiveness of Antidepressants: Comparative Remission Ratesopyright., 3
THE IMPORTANCE OF CHILDHOOD TRAUMA AND CHILDHOOD LIFE Article Abstract Background: Childhood trauma is linked to adult depression and might be a risk factor for a more chronic course of depression. However, the link between childhood trauma and chronicity of depression has not been investigated using a large and representative sample in which other depression characteristics, such as severity, age at onset, and comorbid psychopathology, were FAMOTIDINE AUGMENTATION IN SCHIZOPHRENIA: HOPE OR HYPE Famotidine is a potent, selective histamine H 2 receptor antagonist that has been investigated as an antipsychotic augmentation agent in treatment-refractory schizophrenia, especially for negative symptoms.; Case reports, open studies, and small randomized controlled trials of famotidine have documented differing improvements in total ratings of psychosis, negative symptoms, general RECOGNITION AND DIAGNOSIS OF BIPOLAR DISORDER Recognition and Diagnosis of Bipolar Disorder com-patients. PHARMACOGENOMIC DECISION SUPPORT TOOLS FOR MAJOR Pharmacogenomic Decision Support Tools for Major Depressive Disorder Boadie W. Dunlop, MD, MS Emory University School of Medicine May 30,2020
JOURNAL OF CLINICAL PSYCHIATRY (JCP) Obsessive-Compulsive Disorder and Dementia Risk: A Nationwide Longitudinal Study. Case reports suggest a link between obsessive-compulsive disorder (OCD) and dementia, but this association has received little research. The current study investigated dementia risk among OCD patients using a national health insurance researchdatabase.
REQUEST | PSYCHIATRIST.COM Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be THE MINI-INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW (M.I.N.I J Clin Psychiatry 1998;59 (suppl 20) 23 Development and Validation of the M.I.N.I. © Copyright 1998 Physicians Postgraduate Press, Inc. One personal copy may be printed PREVALENCE, IMPACT, AND BURDEN OF INSOMNIA AND DISCUSSING Prevalence, Impact, and Burden of Insomnia and Discussing It With Patients. Russell P. Rosenberg, PhD. Insomnia is the most prevalent sleep-wake disorder, with about one in ten individuals meeting diagnostic criteria. Associated with significant impairment in daytime function, insomnia has a vast societal burden and impact on publichealth.
TREATING GENERALIZED ANXIETY DISORDER WITH COGNITIVE Treating Generalized Anxiety Disorder With Cognitive 14 cbt. EFFECTIVENESS OF ANTIDEPRESSANTS: COMPARATIVE REMISSION RATES Effectiveness of Antidepressants: Comparative Remission Ratesopyright., 3
THE IMPORTANCE OF CHILDHOOD TRAUMA AND CHILDHOOD LIFE Article Abstract Background: Childhood trauma is linked to adult depression and might be a risk factor for a more chronic course of depression. However, the link between childhood trauma and chronicity of depression has not been investigated using a large and representative sample in which other depression characteristics, such as severity, age at onset, and comorbid psychopathology, were FAMOTIDINE AUGMENTATION IN SCHIZOPHRENIA: HOPE OR HYPE Famotidine is a potent, selective histamine H 2 receptor antagonist that has been investigated as an antipsychotic augmentation agent in treatment-refractory schizophrenia, especially for negative symptoms.; Case reports, open studies, and small randomized controlled trials of famotidine have documented differing improvements in total ratings of psychosis, negative symptoms, general RECOGNITION AND DIAGNOSIS OF BIPOLAR DISORDER Recognition and Diagnosis of Bipolar Disorder com-patients. PHARMACOGENOMIC DECISION SUPPORT TOOLS FOR MAJOR Pharmacogenomic Decision Support Tools for Major Depressive Disorder Boadie W. Dunlop, MD, MS Emory University School of Medicine May 30,2020
ACTION PAGES ARCHIVE See all Topics; AUTHORS/REVIEWERS. Reprints and Permissions; Information for Authors (PCC) Submit a PCC ManuscriptFOCUS ON SUICIDE
The objective of the Focus on Suicide section is to promote scientific research into the causes and prevention of suicide. Identification of risk and protective factors related to suicidal behavior, diagnosis of at-risk persons, evidence-based intervention research, treatment and practice strategies, interdisciplinary approaches, brain imaging and genomic studies are all of interest. In FOCUS ON GERIATRIC PSYCHIATRY To encourage scientific studies relating to the mental health of older adults, JCP is calling for submissions to the Focus on Geriatric Psychiatry, edited by Gary W. Small, MD, and Jordan F. Karp, MD. Topics of interest include late-life depression, memory disorders including Alzheimer’s disease, dementia, grief, anxiety, resilience, and cognition. Manuscripts may address any PSYCHOLOGICAL IMPACT OF THE COVID-19 PANDEMIC AMONG THE T he world is now facing the coronavirus disease 2019 (COVID-19) pandemic, which started in the Wuhan region of China and has spread to most countries around the globe. 1 COVID-19 has affected all aspects of life, resulting in mass panic and hysteria. 2 However, the psychological impact of the pandemic unequally affects different segments of the population, and the elderly are especiallyADHD TREATMENT
Access the latest research and development on ADHD treatment. For the most up-to-date, scientifically rigorous information about attention-deficit/hyperactivity BIPOLAR DISORDER TREATMENT Your source for the latest research on bipolar disorder treatment. When you want access to the most up-to-date information on bipolar disorder treatment, Psychiatrist.com is your go-to source for evidence-based, peer-reviewed articles and research. As a leading resource for psychiatric information, Psychiatrist.com offers access to a wide range of material that explores the newest advances in TREATMENT-RESISTANT SCHIZOPHRENIA GUIDELINE S chizophrenia is a complex, progressive, and severe mental disorder characterized by distortions in thinking, perception, emotions, language, sense of self, and behavior. 1 It is estimated that over 21 million people worldwide have schizophrenia. 1 The majority of people with this illness exhibit a prodromal period characterized by subtle changes in thoughts and perceptions, followed by the ADHD TEST | PSYCHIATRIST.COM Access the latest research on ADHD tests. When you’re looking for the most up-to-date articles on ADHD tests, Psychiatrist.com offers access to a rich collection of DELIRIOUS MANIA: AN APPROACH TO DIAGNOSIS AND TREATMENT Close monitoring for respiratory suppression, or alternatively for paradoxical worsening of confusion, is recommended during lorazepam challenge. If no improvement occurs, electroconvulsive therapy (ECT) should be considered. 2 ECT is the most effective treatment to resolve symptoms and signs of delirious mania within 2 to 4 sessions, although A RAPIDLY REVERSED CASE OF SYMPTOMS CONSISTENT WITH When there is suspicion for neuroleptic malignant syndrome, prompt medical therapy and discontinuation of the offending agent are crucial. This report presents JOURNAL OF CLINICAL PSYCHIATRY (JCP) Obsessive-Compulsive Disorder and Dementia Risk: A Nationwide Longitudinal Study. Case reports suggest a link between obsessive-compulsive disorder (OCD) and dementia, but this association has received little research. The current study investigated dementia risk among OCD patients using a national health insurance researchdatabase.
REQUEST | PSYCHIATRIST.COM Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be THE MINI-INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW (M.I.N.I J Clin Psychiatry 1998;59 (suppl 20) 23 Development and Validation of the M.I.N.I. © Copyright 1998 Physicians Postgraduate Press, Inc. One personal copy may be printed PREVALENCE, IMPACT, AND BURDEN OF INSOMNIA AND DISCUSSING Prevalence, Impact, and Burden of Insomnia and Discussing It With Patients. Russell P. Rosenberg, PhD. Insomnia is the most prevalent sleep-wake disorder, with about one in ten individuals meeting diagnostic criteria. Associated with significant impairment in daytime function, insomnia has a vast societal burden and impact on publichealth.
TREATING GENERALIZED ANXIETY DISORDER WITH COGNITIVE Treating Generalized Anxiety Disorder With Cognitive 14 cbt. EFFECTIVENESS OF ANTIDEPRESSANTS: COMPARATIVE REMISSION RATES Effectiveness of Antidepressants: Comparative Remission Ratesopyright., 3
THE IMPORTANCE OF CHILDHOOD TRAUMA AND CHILDHOOD LIFE Article Abstract Background: Childhood trauma is linked to adult depression and might be a risk factor for a more chronic course of depression. However, the link between childhood trauma and chronicity of depression has not been investigated using a large and representative sample in which other depression characteristics, such as severity, age at onset, and comorbid psychopathology, were FAMOTIDINE AUGMENTATION IN SCHIZOPHRENIA: HOPE OR HYPE Famotidine is a potent, selective histamine H 2 receptor antagonist that has been investigated as an antipsychotic augmentation agent in treatment-refractory schizophrenia, especially for negative symptoms.; Case reports, open studies, and small randomized controlled trials of famotidine have documented differing improvements in total ratings of psychosis, negative symptoms, general RECOGNITION AND DIAGNOSIS OF BIPOLAR DISORDER Recognition and Diagnosis of Bipolar Disorder com-patients. PHARMACOGENOMIC DECISION SUPPORT TOOLS FOR MAJOR Pharmacogenomic Decision Support Tools for Major Depressive Disorder Boadie W. Dunlop, MD, MS Emory University School of Medicine May 30,2020
JOURNAL OF CLINICAL PSYCHIATRY (JCP) Obsessive-Compulsive Disorder and Dementia Risk: A Nationwide Longitudinal Study. Case reports suggest a link between obsessive-compulsive disorder (OCD) and dementia, but this association has received little research. The current study investigated dementia risk among OCD patients using a national health insurance researchdatabase.
REQUEST | PSYCHIATRIST.COM Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be THE MINI-INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW (M.I.N.I J Clin Psychiatry 1998;59 (suppl 20) 23 Development and Validation of the M.I.N.I. © Copyright 1998 Physicians Postgraduate Press, Inc. One personal copy may be printed PREVALENCE, IMPACT, AND BURDEN OF INSOMNIA AND DISCUSSING Prevalence, Impact, and Burden of Insomnia and Discussing It With Patients. Russell P. Rosenberg, PhD. Insomnia is the most prevalent sleep-wake disorder, with about one in ten individuals meeting diagnostic criteria. Associated with significant impairment in daytime function, insomnia has a vast societal burden and impact on publichealth.
TREATING GENERALIZED ANXIETY DISORDER WITH COGNITIVE Treating Generalized Anxiety Disorder With Cognitive 14 cbt. EFFECTIVENESS OF ANTIDEPRESSANTS: COMPARATIVE REMISSION RATES Effectiveness of Antidepressants: Comparative Remission Ratesopyright., 3
THE IMPORTANCE OF CHILDHOOD TRAUMA AND CHILDHOOD LIFE Article Abstract Background: Childhood trauma is linked to adult depression and might be a risk factor for a more chronic course of depression. However, the link between childhood trauma and chronicity of depression has not been investigated using a large and representative sample in which other depression characteristics, such as severity, age at onset, and comorbid psychopathology, were FAMOTIDINE AUGMENTATION IN SCHIZOPHRENIA: HOPE OR HYPE Famotidine is a potent, selective histamine H 2 receptor antagonist that has been investigated as an antipsychotic augmentation agent in treatment-refractory schizophrenia, especially for negative symptoms.; Case reports, open studies, and small randomized controlled trials of famotidine have documented differing improvements in total ratings of psychosis, negative symptoms, general RECOGNITION AND DIAGNOSIS OF BIPOLAR DISORDER Recognition and Diagnosis of Bipolar Disorder com-patients. PHARMACOGENOMIC DECISION SUPPORT TOOLS FOR MAJOR Pharmacogenomic Decision Support Tools for Major Depressive Disorder Boadie W. Dunlop, MD, MS Emory University School of Medicine May 30,2020
ACTION PAGES ARCHIVE See all Topics; AUTHORS/REVIEWERS. Reprints and Permissions; Information for Authors (PCC) Submit a PCC ManuscriptFOCUS ON SUICIDE
The objective of the Focus on Suicide section is to promote scientific research into the causes and prevention of suicide. Identification of risk and protective factors related to suicidal behavior, diagnosis of at-risk persons, evidence-based intervention research, treatment and practice strategies, interdisciplinary approaches, brain imaging and genomic studies are all of interest. In FOCUS ON GERIATRIC PSYCHIATRY To encourage scientific studies relating to the mental health of older adults, JCP is calling for submissions to the Focus on Geriatric Psychiatry, edited by Gary W. Small, MD, and Jordan F. Karp, MD. Topics of interest include late-life depression, memory disorders including Alzheimer’s disease, dementia, grief, anxiety, resilience, and cognition. Manuscripts may address any PSYCHOLOGICAL IMPACT OF THE COVID-19 PANDEMIC AMONG THE T he world is now facing the coronavirus disease 2019 (COVID-19) pandemic, which started in the Wuhan region of China and has spread to most countries around the globe. 1 COVID-19 has affected all aspects of life, resulting in mass panic and hysteria. 2 However, the psychological impact of the pandemic unequally affects different segments of the population, and the elderly are especiallyADHD TREATMENT
Access the latest research and development on ADHD treatment. For the most up-to-date, scientifically rigorous information about attention-deficit/hyperactivity BIPOLAR DISORDER TREATMENT Your source for the latest research on bipolar disorder treatment. When you want access to the most up-to-date information on bipolar disorder treatment, Psychiatrist.com is your go-to source for evidence-based, peer-reviewed articles and research. As a leading resource for psychiatric information, Psychiatrist.com offers access to a wide range of material that explores the newest advances in TREATMENT-RESISTANT SCHIZOPHRENIA GUIDELINE S chizophrenia is a complex, progressive, and severe mental disorder characterized by distortions in thinking, perception, emotions, language, sense of self, and behavior. 1 It is estimated that over 21 million people worldwide have schizophrenia. 1 The majority of people with this illness exhibit a prodromal period characterized by subtle changes in thoughts and perceptions, followed by the ADHD TEST | PSYCHIATRIST.COM Access the latest research on ADHD tests. When you’re looking for the most up-to-date articles on ADHD tests, Psychiatrist.com offers access to a rich collection of DELIRIOUS MANIA: AN APPROACH TO DIAGNOSIS AND TREATMENT Close monitoring for respiratory suppression, or alternatively for paradoxical worsening of confusion, is recommended during lorazepam challenge. If no improvement occurs, electroconvulsive therapy (ECT) should be considered. 2 ECT is the most effective treatment to resolve symptoms and signs of delirious mania within 2 to 4 sessions, although A RAPIDLY REVERSED CASE OF SYMPTOMS CONSISTENT WITH When there is suspicion for neuroleptic malignant syndrome, prompt medical therapy and discontinuation of the offending agent are crucial. This report presents REQUEST | PSYCHIATRIST.COM Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be THE MINI-INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW (M.I.N.I J Clin Psychiatry 1998;59 (suppl 20) 23 Development and Validation of the M.I.N.I. © Copyright 1998 Physicians Postgraduate Press, Inc. One personal copy may be printed ADHD AND COMORBIDITY IN CHILDHOOD ' COPYRIGHT 2006 PHYSICIANS POSTGRADUATE PRESS, INC.. ' COPYRIGHT 2006 PHYSICIANS POSTGRADUATE PRESS, INC. Comorbidities of Childhood ADHD J Clin Psychiatry 2006;67 (suppl 8) 27 ADHD and Comorbidity in Childhood Thomas J. Spencer, M.D. In recent years, evidence has been accumulating regarding high levels of comorbidity between PREVALENCE, IMPACT, AND BURDEN OF INSOMNIA AND DISCUSSING Prevalence, Impact, and Burden of Insomnia and Discussing It With Patients. Russell P. Rosenberg, PhD. Insomnia is the most prevalent sleep-wake disorder, with about one in ten individuals meeting diagnostic criteria. Associated with significant impairment in daytime function, insomnia has a vast societal burden and impact on publichealth.
EFFECTIVENESS OF ANTIDEPRESSANTS: COMPARATIVE REMISSION RATES Effectiveness of Antidepressants: Comparative Remission Ratesopyright., 3
THE EFFECTS OF BENZODIAZEPINES ON COGNITION Samantha A. Stewart 10 J Clin Psychiatry 2005;66 (suppl 2) of new information as it occurred (such as details of events that took place en route).3 It has been argued that such memory loss can be attributed to the sedative effects that NEUROBIOLOGY AND ETIOLOGY OF PANIC DISORDER Neurobiology and Etiology of Panic Disorder J Clin Psychiatry 2005;66 (suppl 4) 5 an emotional memory—a strengthening of synapses in the lateral nucleus of the amygdala that represent the experi- DELIRIOUS MANIA: AN APPROACH TO DIAGNOSIS AND TREATMENT Close monitoring for respiratory suppression, or alternatively for paradoxical worsening of confusion, is recommended during lorazepam challenge. If no improvement occurs, electroconvulsive therapy (ECT) should be considered. 2 ECT is the most effective treatment to resolve symptoms and signs of delirious mania within 2 to 4 sessions, although NEUROPATHOLOGIC CHANGES IN ALZHEIMER’S DISEASE COPYRIGHT 2003 PHYSICIANS POSTGRADUATE PRESS, INC. © COPYRIGHT 2003 PHYSICIANS POSTGRADUATE PRESS, INC. Gary L. Wenk 8 J Clin Psychiatry 2003;64 (suppl 9) still RELATIONSHIP OF NEUROTRANSMITTERS TO THE SYMPTOMS OF MAJOR Neurotransmitters and Symptoms of MDD J Clin Psychiatry 2008;69 (suppl E1) PSYCHIATRIST.COM 5 that if an agent blocked only serotonin uptake, it could have antidepressant qualities without as REQUEST | PSYCHIATRIST.COM Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be THE MINI-INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW (M.I.N.I J Clin Psychiatry 1998;59 (suppl 20) 23 Development and Validation of the M.I.N.I. © Copyright 1998 Physicians Postgraduate Press, Inc. One personal copy may be printed ADHD AND COMORBIDITY IN CHILDHOOD ' COPYRIGHT 2006 PHYSICIANS POSTGRADUATE PRESS, INC.. ' COPYRIGHT 2006 PHYSICIANS POSTGRADUATE PRESS, INC. Comorbidities of Childhood ADHD J Clin Psychiatry 2006;67 (suppl 8) 27 ADHD and Comorbidity in Childhood Thomas J. Spencer, M.D. In recent years, evidence has been accumulating regarding high levels of comorbidity between PREVALENCE, IMPACT, AND BURDEN OF INSOMNIA AND DISCUSSING Prevalence, Impact, and Burden of Insomnia and Discussing It With Patients. Russell P. Rosenberg, PhD. Insomnia is the most prevalent sleep-wake disorder, with about one in ten individuals meeting diagnostic criteria. Associated with significant impairment in daytime function, insomnia has a vast societal burden and impact on publichealth.
EFFECTIVENESS OF ANTIDEPRESSANTS: COMPARATIVE REMISSION RATES Effectiveness of Antidepressants: Comparative Remission Ratesopyright., 3
THE EFFECTS OF BENZODIAZEPINES ON COGNITION Samantha A. Stewart 10 J Clin Psychiatry 2005;66 (suppl 2) of new information as it occurred (such as details of events that took place en route).3 It has been argued that such memory loss can be attributed to the sedative effects that NEUROBIOLOGY AND ETIOLOGY OF PANIC DISORDER Neurobiology and Etiology of Panic Disorder J Clin Psychiatry 2005;66 (suppl 4) 5 an emotional memory—a strengthening of synapses in the lateral nucleus of the amygdala that represent the experi- DELIRIOUS MANIA: AN APPROACH TO DIAGNOSIS AND TREATMENT Close monitoring for respiratory suppression, or alternatively for paradoxical worsening of confusion, is recommended during lorazepam challenge. If no improvement occurs, electroconvulsive therapy (ECT) should be considered. 2 ECT is the most effective treatment to resolve symptoms and signs of delirious mania within 2 to 4 sessions, although NEUROPATHOLOGIC CHANGES IN ALZHEIMER’S DISEASE COPYRIGHT 2003 PHYSICIANS POSTGRADUATE PRESS, INC. © COPYRIGHT 2003 PHYSICIANS POSTGRADUATE PRESS, INC. Gary L. Wenk 8 J Clin Psychiatry 2003;64 (suppl 9) still RELATIONSHIP OF NEUROTRANSMITTERS TO THE SYMPTOMS OF MAJOR Neurotransmitters and Symptoms of MDD J Clin Psychiatry 2008;69 (suppl E1) PSYCHIATRIST.COM 5 that if an agent blocked only serotonin uptake, it could have antidepressant qualities without as PSYCHIATRIST.COM: JCP, PCC, AND THE CME INSTITUTE In this study, 25 overweight or obese women with major depressive disorder received up to 24 weeks of open-label treatment with a combination of 32 mg per day of naltrexone sustained-release and 360 mg per day of bupropion sustained release, along with dietary and behavioral counseling. Susan L. JOURNAL OF CLINICAL PSYCHIATRY (JCP) Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be DEPRESSION (MDD) ARCHIVES Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be THE MINI-INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW (M.I.N.I J Clin Psychiatry 1998;59 (suppl 20) 23 Development and Validation of the M.I.N.I. © Copyright 1998 Physicians Postgraduate Press, Inc. One personal copy may be printed TREATMENT-RESISTANT SCHIZOPHRENIA: A BRIEF OVERVIEW OF A lthough antipsychotic medications have been the mainstay of treatment for schizophrenia, approximately one-third of individuals with schizophrenia show a limited response to antipsychotic treatment, 1 which has led to the term treatment-resistant schizophrenia (TRS). 2 The static failure to respond to treatment suggests that schizophrenia is a heterogeneous condition with POSTTRAUMATIC STRESS DISORDER AND COMORBIDITY: RECOGNIZING Copyright 1997 Physicians Postgraduate Press, Inc. One personal copy may be printed 14 J Clin Psychiatry 1997;58 (suppl 9) Kathleen T. Brady present as panic attacks. ELECTROCONVULSIVE THERAPY IN SEVERE OBSESSIVE-COMPULSIVE O bsessive-compulsive disorder (OCD) is a chronic psychiatric disorder characterized by recurrent persistent thoughts and repetitive compulsory behaviors that cause significant dysfunction. 1 Currently, cognitive-behavioral therapy and selective serotonin reuptake inhibitors are considered first-line treatments in its management. Previous studies 2 have reported that 25%-40% of patients have NEUROPATHOLOGIC CHANGES IN ALZHEIMER’S DISEASE COPYRIGHT 2003 PHYSICIANS POSTGRADUATE PRESS, INC. © COPYRIGHT 2003 PHYSICIANS POSTGRADUATE PRESS, INC. Neuropathologic Changes J Clin Psychiatry 2003;64 (suppl 9 INVESTIGATIONAL TREATMENT OF DEPRESSIVE DISORDERS WITH Recent promising data indicate that neuroactive steroids could have a role in treating depression. This article discusses the mechanisms behind potential beneficial LETTERS TO THE EDITOR LETTERS TO THE EDITOR 334 J Clin Psychiatry 68:2, February 2007 Dr. Sweitzer and Colleagues Reply Sir: Dr. Gharabawi’s recent letter regarding the trials con- ducted by Potkin et al.1 and Zhong et al.2 highlights several sa- lient points on the interpretation of data fromcomparative
PSYCHIATRIST.COM: JCP, PCC, AND THE CME INSTITUTE In this study, 25 overweight or obese women with major depressive disorder received up to 24 weeks of open-label treatment with a combination of 32 mg per day of naltrexone sustained-release and 360 mg per day of bupropion sustained release, along with dietary and behavioral counseling. Susan L. JOURNAL OF CLINICAL PSYCHIATRY (JCP) Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be REQUEST | PSYCHIATRIST.COM Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be PREVALENCE, IMPACT, AND BURDEN OF INSOMNIA AND DISCUSSING Prevalence, Impact, and Burden of Insomnia and Discussing It With Patients. Russell P. Rosenberg, PhD. Insomnia is the most prevalent sleep-wake disorder, with about one in ten individuals meeting diagnostic criteria. Associated with significant impairment in daytime function, insomnia has a vast societal burden and impact on publichealth.
PHENIBUT DEPENDENCE AND WITHDRAWAL Phenibut is a neuropsychotropic drug that is currently used at increasing rates due to online availability as an unregulated supplement.Case reports 1, 2 have shown its potential to produce abuse and dependence and withdrawal symptoms after discontinuation. Research 3 has shown that drugs with similar structures can be utilized to alleviate phenibut withdrawal symptoms. NEUROPATHOLOGIC CHANGES IN ALZHEIMER’S DISEASE COPYRIGHT 2003 PHYSICIANS POSTGRADUATE PRESS, INC. © COPYRIGHT 2003 PHYSICIANS POSTGRADUATE PRESS, INC. Gary L. Wenk 8 J Clin Psychiatry 2003;64 (suppl 9) still DELIRIOUS MANIA: AN APPROACH TO DIAGNOSIS AND TREATMENT Close monitoring for respiratory suppression, or alternatively for paradoxical worsening of confusion, is recommended during lorazepam challenge. If no improvement occurs, electroconvulsive therapy (ECT) should be considered. 2 ECT is the most effective treatment to resolve symptoms and signs of delirious mania within 2 to 4 sessions, although LETTERS TO THE EDITOR LETTERS TO THE EDITOR 334 J Clin Psychiatry 68:2, February 2007 Dr. Sweitzer and Colleagues Reply Sir: Dr. Gharabawi’s recent letter regarding the trials con- ducted by Potkin et al.1 and Zhong et al.2 highlights several sa- lient points on the interpretation of data fromcomparative
INTERVENTION AND RESILIENCE AFTER MASS TRAUMA Intervention and Resilience After Mass Trauma. edited by Michael Blumenfield, MD, and Robert J. Ursano, MD. Cambridge University Press, New York, NY, 2008, 186 pages, $72.00 (includes CD-ROM). Growing out of a 2006 conference exploring the psychological interventions following mass trauma, this book aspires to capture the "state of theart" in
THE IMPORTANCE OF CHILDHOOD TRAUMA AND CHILDHOOD LIFE Article Abstract Background: Childhood trauma is linked to adult depression and might be a risk factor for a more chronic course of depression. However, the link between childhood trauma and chronicity of depression has not been investigated using a large and representative sample in which other depression characteristics, such as severity, age at onset, and comorbid psychopathology, were PSYCHIATRIST.COM: JCP, PCC, AND THE CME INSTITUTE In this study, 25 overweight or obese women with major depressive disorder received up to 24 weeks of open-label treatment with a combination of 32 mg per day of naltrexone sustained-release and 360 mg per day of bupropion sustained release, along with dietary and behavioral counseling. Susan L. JOURNAL OF CLINICAL PSYCHIATRY (JCP) Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be REQUEST | PSYCHIATRIST.COM Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be PREVALENCE, IMPACT, AND BURDEN OF INSOMNIA AND DISCUSSING Prevalence, Impact, and Burden of Insomnia and Discussing It With Patients. Russell P. Rosenberg, PhD. Insomnia is the most prevalent sleep-wake disorder, with about one in ten individuals meeting diagnostic criteria. Associated with significant impairment in daytime function, insomnia has a vast societal burden and impact on publichealth.
PHENIBUT DEPENDENCE AND WITHDRAWAL Phenibut is a neuropsychotropic drug that is currently used at increasing rates due to online availability as an unregulated supplement.Case reports 1, 2 have shown its potential to produce abuse and dependence and withdrawal symptoms after discontinuation. Research 3 has shown that drugs with similar structures can be utilized to alleviate phenibut withdrawal symptoms. NEUROPATHOLOGIC CHANGES IN ALZHEIMER’S DISEASE COPYRIGHT 2003 PHYSICIANS POSTGRADUATE PRESS, INC. © COPYRIGHT 2003 PHYSICIANS POSTGRADUATE PRESS, INC. Gary L. Wenk 8 J Clin Psychiatry 2003;64 (suppl 9) still DELIRIOUS MANIA: AN APPROACH TO DIAGNOSIS AND TREATMENT Close monitoring for respiratory suppression, or alternatively for paradoxical worsening of confusion, is recommended during lorazepam challenge. If no improvement occurs, electroconvulsive therapy (ECT) should be considered. 2 ECT is the most effective treatment to resolve symptoms and signs of delirious mania within 2 to 4 sessions, although LETTERS TO THE EDITOR LETTERS TO THE EDITOR 334 J Clin Psychiatry 68:2, February 2007 Dr. Sweitzer and Colleagues Reply Sir: Dr. Gharabawi’s recent letter regarding the trials con- ducted by Potkin et al.1 and Zhong et al.2 highlights several sa- lient points on the interpretation of data fromcomparative
INTERVENTION AND RESILIENCE AFTER MASS TRAUMA Intervention and Resilience After Mass Trauma. edited by Michael Blumenfield, MD, and Robert J. Ursano, MD. Cambridge University Press, New York, NY, 2008, 186 pages, $72.00 (includes CD-ROM). Growing out of a 2006 conference exploring the psychological interventions following mass trauma, this book aspires to capture the "state of theart" in
THE IMPORTANCE OF CHILDHOOD TRAUMA AND CHILDHOOD LIFE Article Abstract Background: Childhood trauma is linked to adult depression and might be a risk factor for a more chronic course of depression. However, the link between childhood trauma and chronicity of depression has not been investigated using a large and representative sample in which other depression characteristics, such as severity, age at onset, and comorbid psychopathology, were PSYCHIATRIST.COM: JCP, PCC, AND THE CME INSTITUTE Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be DEPRESSION (MDD) ARCHIVES Impact of COVID-19 on a Patient With Depression and Suicidal Ideation. A wide range of psychological outcomes have been observed during the COVID-19 outbreak. Patients often experience the fear of getting sick or dying and feel helpless or stereotyped by others. Read this case report to find out more. Neda Motamedi & more. JOURNAL OF CLINICAL PSYCHIATRY (JCP) Electroconvulsive therapy (ECT) use in children and adolescents is much less common than in adults, and the evidence base for its use in youth is limited. This study reports outcomes of a cohort of youth treated with ECT at an academic medical center. Matthew D. Pierson,Brian
INFORMATION FOR AUTHORS (JCP) Free Access Option. The Journal of Clinical Psychiatry: The JCP offers authors of accepted articles and letters the opportunity to make their article or letter freely available to nonsubscribers on JCP’s Web site, Psychiatrist.com. The charge for this service is $3,000 and is payable by check or credit card. TOOLS TO ASSESS NEGATIVE SYMPTOMS IN SCHIZOPHRENIA Article AbstractAlthough effective treatments for negative symptoms are currently limited, clinicians still need to assess and monitor them because of their impact on patient functioning. Further, documenting patients†negative symptoms provides a complete clinical record that the clinician can use to make systematic and careful treatment decisions. Several tools for assessing negative DEPRESSION (MDD) ARCHIVES Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be INVESTIGATIONAL TREATMENT OF DEPRESSIVE DISORDERS WITH Recent promising data indicate that neuroactive steroids could have a role in treating depression. This article discusses the mechanisms behind potential beneficial HEMORRHOIDS IN OBSESSIVE-COMPULSIVE DISORDER Obsessive-compulsive disorder (OCD), when it becomes chronic, rarely can manifest with secondary physical conditions. 1 Here, we report the case of a young male patient who developed hemorrhoids and life-threatening anal bleeding as a result of OCD.. Case Report. A 20-year-old man presented to the outpatient surgery department of our hospital with complaints of bleeding from the rectum and was POLYPHARMACY AND THE CONCEPT OF A “FOUNDATIONAL TREATMENT Learn how simplifying a bipolar disorder treatment regimen, with a single agent acting as the “foundation” and others added when needed, may both improve patient morale and be effective for symptom control. Read the full Academic Highlights RESIDUAL SYMPTOMS SEEN IN PATIENTS WITH INADEQUATE An expert panel describes residual symptoms often seen in patients with major depressive disorder who have inadequate response to antidepressants. Read the eReport PSYCHIATRIST.COM: JCP, PCC, AND THE CME INSTITUTE Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be JOURNAL OF CLINICAL PSYCHIATRY (JCP) Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be REQUEST | PSYCHIATRIST.COM Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be PREVALENCE, IMPACT, AND BURDEN OF INSOMNIA AND DISCUSSING Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be INTERVENTION AND RESILIENCE AFTER MASS TRAUMA Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be DELIRIOUS MANIA: AN APPROACH TO DIAGNOSIS AND TREATMENT Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen PHENIBUT DEPENDENCE AND WITHDRAWAL Phenibut is a neuropsychotropic drug that is currently used at increasing rates due to online availability as an unregulated supplement.Case reports 1, 2 have shown its potential to produce abuse and dependence and withdrawal symptoms after discontinuation. Research 3 has shown that drugs with similar structures can be utilized to alleviate phenibut withdrawal symptoms. NEUROPATHOLOGIC CHANGES IN ALZHEIMER’S DISEASE COPYRIGHT 2003 PHYSICIANS POSTGRADUATE PRESS, INC. © COPYRIGHT 2003 PHYSICIANS POSTGRADUATE PRESS, INC. Gary L. Wenk 8 J Clin Psychiatry 2003;64 (suppl 9) still LETTERS TO THE EDITOR LETTERS TO THE EDITOR 334 J Clin Psychiatry 68:2, February 2007 Dr. Sweitzer and Colleagues Reply Sir: Dr. Gharabawi’s recent letter regarding the trials con- ducted by Potkin et al.1 and Zhong et al.2 highlights several sa- lient points on the interpretation of data fromcomparative
THE IMPORTANCE OF CHILDHOOD TRAUMA AND CHILDHOOD LIFE Article Abstract Background: Childhood trauma is linked to adult depression and might be a risk factor for a more chronic course of depression. However, the link between childhood trauma and chronicity of depression has not been investigated using a large and representative sample in which other depression characteristics, such as severity, age at onset, and comorbid psychopathology, were PSYCHIATRIST.COM: JCP, PCC, AND THE CME INSTITUTE Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be JOURNAL OF CLINICAL PSYCHIATRY (JCP) Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be REQUEST | PSYCHIATRIST.COM Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be PREVALENCE, IMPACT, AND BURDEN OF INSOMNIA AND DISCUSSING Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be INTERVENTION AND RESILIENCE AFTER MASS TRAUMA Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be DELIRIOUS MANIA: AN APPROACH TO DIAGNOSIS AND TREATMENT Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen PSYCHIATRIST.COM: JCP, PCC, AND THE CME INSTITUTE Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be DEPRESSION (MDD) ARCHIVES Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be JOURNAL OF CLINICAL PSYCHIATRY (JCP) Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be DEPRESSION (MDD) ARCHIVES Baclofen, a French Exception, Seriously Harms Alcohol Use Disorder Patients Without Benefit To the Editor: Dr Andrade’s analysis of the Bacloville trial in a recent Clinical and Practical Psychopharmacology column, in which he concluded that “individualized treatment with high-dose baclofen (30-300 mg/d) may be a useful second-line approach in heavy drinkers” and that “baclofen may be INFORMATION FOR AUTHORS (JCP) MANUSCRIPT SUBMISSION We encourage you to submit your manuscript if it fits within the scope of The Journal of Clinical Psychiatry. Acceptance is contingent on favorable peer review. Our user-friendly electronic manuscript submission and peer-review system allows you to submit your manuscript online securely, conveniently, and instantly. The system will request that new authors register for an HEMORRHOIDS IN OBSESSIVE-COMPULSIVE DISORDER Obsessive-compulsive disorder (OCD), when it becomes chronic, rarely can manifest with secondary physical conditions. 1 Here, we report the case of a young male patient who developed hemorrhoids and life-threatening anal bleeding as a result of OCD.. Case Report. A 20-year-old man presented to the outpatient surgery department of our hospital with complaints of bleeding from the rectum and was TOOLS TO ASSESS NEGATIVE SYMPTOMS IN SCHIZOPHRENIA Article AbstractAlthough effective treatments for negative symptoms are currently limited, clinicians still need to assess and monitor them because of their impact on patient functioning. Further, documenting patients†negative symptoms provides a complete clinical record that the clinician can use to make systematic and careful treatment decisions. Several tools for assessing negative RESIDUAL SYMPTOMS SEEN IN PATIENTS WITH INADEQUATE An expert panel describes residual symptoms often seen in patients with major depressive disorder who have inadequate response to antidepressants. Read the eReport POLYPHARMACY AND THE CONCEPT OF A “FOUNDATIONAL TREATMENT Learn how simplifying a bipolar disorder treatment regimen, with a single agent acting as the “foundation” and others added when needed, may both improve patient morale and be effective for symptom control. Read the full Academic Highlights CHRONOBIOLOGICAL RHYTHMS, HOPELESSNESS, AND SUICIDE RISK Objective: To examine the role of chronobiological dysrhythmicity in suicidal ideation and behaviors and its relation with hopelessness. Methods: One hundred twenty-seven patients (77 females, mean age of 47.4 ± 12.5 years) with a major depressive episode and bipolar disorder (BD) type I or II (according to Structured Clinical Interview for DSM-5 assessment) were recruited in 2019 andPSYCHIATRIST.COM
CME Institute
Home | About Us
| Mission
Statement | All
CME Activities | MyCME|
|
JCP
Home | About JCP
| Subscribe
| Archive
| Information for Authors| Information
for Reviewers
| Information
for Advertisers
| Customer
Service |
|
PCC
Home | About PCC
| Register
| Archive
| Information for Authors | Information for Reviewers|
|
Help
FAQ | About
Psychiatrist.com | Terms of use| Privacy
policy
*
* Advanced Search
Login
Login
Login | Login Help | Register| Subscribe
Subscribe to JCP
| Elerts
Page Content
Manage Subscriptions /_layouts/images/ReportServer/Manage_Subscription.gif /_layouts/ReportServer/ManageSubscriptions.aspx?list={ListId}&ID={ItemId}0x80
0x0
FileType
rdl
350
Manage Data Sources
/_layouts/ReportServer/DataSourceList.aspx?list={ListId}&ID={ItemId}0x0
0x20
FileType
rdl
351
Manage Shared Datasets /_layouts/ReportServer/DatasetList.aspx?list={ListId}&ID={ItemId}0x0
0x20
FileType
rdl
352
Manage Parameters
/_layouts/ReportServer/ParameterList.aspx?list={ListId}&ID={ItemId}0x0
0x4
FileType
rdl
353
Manage Processing Options /_layouts/ReportServer/ReportExecution.aspx?list={ListId}&ID={ItemId}0x0
0x4
FileType
rdl
354
Manage Cache Refresh Plans /_layouts/ReportServer/CacheRefreshPlanList.aspx?list={ListId}&ID={ItemId}0x0
0x4
FileType
rdl
355
View Report History
/_layouts/ReportServer/ReportHistory.aspx?list={ListId}&ID={ItemId}0x0
0x40
FileType
rdl
356
View Dependent Items /_layouts/ReportServer/DependentItems.aspx?list={ListId}&ID={ItemId}0x0
0x4
FileType
rsds
350
Edit Data Source Definition /_layouts/ReportServer/SharedDataSource.aspx?list={ListId}&ID={ItemId}0x0
0x4
FileType
rsds
351
View Dependent Items /_layouts/ReportServer/DependentItems.aspx?list={ListId}&ID={ItemId}0x0
0x4
FileType
smdl
350
Manage Clickthrough Reports /_layouts/ReportServer/ModelClickThrough.aspx?list={ListId}&ID={ItemId}0x0
0x4
FileType
smdl
352
Manage Model Item Security /_layouts/ReportServer/ModelItemSecurity.aspx?list={ListId}&ID={ItemId}0x0
0x2000000
FileType
smdl
353
Regenerate Model
/_layouts/ReportServer/GenerateModel.aspx?list={ListId}&ID={ItemId}0x0
0x4
FileType
smdl
354
Manage Data Sources
/_layouts/ReportServer/DataSourceList.aspx?list={ListId}&ID={ItemId}0x0
0x20
FileType
smdl
351
Load in Report Builder /_layouts/ReportServer/RSAction.aspx?RSAction=ReportBuilderModelContext&list={ListId}&ID={ItemId}0x0
0x2
FileType
smdl
250
Edit in Report Builder /_layouts/images/ReportServer/EditReport.gif /_layouts/ReportServer/RSAction.aspx?RSAction=ReportBuilderReportContext&list={ListId}&ID={ItemId}0x0
0x4
FileType
rdl
250
Edit in Report Builder /_layouts/ReportServer/RSAction.aspx?RSAction=ReportBuilderDatasetContext&list={ListId}&ID={ItemId}0x0
0x4
FileType
rsd
250
Manage Caching Options /_layouts/ReportServer/DatasetCachingOptions.aspx?list={ListId}&ID={ItemId}0x0
0x4
FileType
rsd
350
Manage Cache Refresh Plans /_layouts/ReportServer/CacheRefreshPlanList.aspx?list={ListId}&ID={ItemId}&IsDataset=true0x0
0x4
FileType
rsd
351
Manage Data Sources
/_layouts/ReportServer/DataSourceList.aspx?list={ListId}&ID={ItemId}0x0
0x20
FileType
rsd
352
View Dependent Items /_layouts/ReportServer/DependentItems.aspx?list={ListId}&ID={ItemId}0x0
0x4
FileType
rsd
353
Compliance Details
javascript:commonShowModalDialog('{SiteUrl}/_layouts/itemexpiration.aspx?ID={ItemId}&List={ListId}', 'center:1;dialogHeight:500px;dialogWidth:500px;resizable:yes;status:no;location:no;menubar:no;help:no', function GotoPageAfterClose(pageid){if(pageid == 'hold') {STSNavigate(unescape(decodeURI('{SiteUrl}'))+'/_layouts/hold.aspx?ID={ItemId}&List={ListId}'); return false;} if(pageid == 'audit') {STSNavigate(unescape(decodeURI('{SiteUrl}'))+'/_layouts/Reporting.aspx?Category=Auditing&backtype=item&ID={ItemId}&List={ListId}'); return false;} if(pageid == 'config') {STSNavigate(unescape(decodeURI('{SiteUrl}'))+'/_layouts/expirationconfig.aspx?ID={ItemId}&List={ListId}'); return false;}}, null); return false;0x0
0x1
ContentType
0x01
898
Document Set Version History javascript:SP.UI.ModalDialog.ShowPopupDialog('{SiteUrl}/_layouts/DocSetVersions.aspx?List={ListId}&ID={ItemId}')0x0
0x0
ContentType
0x0120D520
330
Send To other location javascript:GoToPage('{SiteUrl}/_layouts/docsetsend.aspx?List={ListId}&ID={ItemId}')0x0
0x0
ContentType
0x0120D520
350
Manage Subscriptions /_layouts/images/ReportServer/Manage_Subscription.gif /_layouts/ReportServer/ManageSubscriptions.aspx?list={ListId}&ID={ItemId}0x80
0x0
FileType
rdl
350
Manage Data Sources
/_layouts/ReportServer/DataSourceList.aspx?list={ListId}&ID={ItemId}0x0
0x20
FileType
rdl
351
Manage Shared Datasets /_layouts/ReportServer/DatasetList.aspx?list={ListId}&ID={ItemId}0x0
0x20
FileType
rdl
352
Manage Parameters
/_layouts/ReportServer/ParameterList.aspx?list={ListId}&ID={ItemId}0x0
0x4
FileType
rdl
353
Manage Processing Options /_layouts/ReportServer/ReportExecution.aspx?list={ListId}&ID={ItemId}0x0
0x4
FileType
rdl
354
Manage Cache Refresh Plans /_layouts/ReportServer/CacheRefreshPlanList.aspx?list={ListId}&ID={ItemId}0x0
0x4
FileType
rdl
355
View Report History
/_layouts/ReportServer/ReportHistory.aspx?list={ListId}&ID={ItemId}0x0
0x40
FileType
rdl
356
View Dependent Items /_layouts/ReportServer/DependentItems.aspx?list={ListId}&ID={ItemId}0x0
0x4
FileType
rsds
350
Edit Data Source Definition /_layouts/ReportServer/SharedDataSource.aspx?list={ListId}&ID={ItemId}0x0
0x4
FileType
rsds
351
View Dependent Items /_layouts/ReportServer/DependentItems.aspx?list={ListId}&ID={ItemId}0x0
0x4
FileType
smdl
350
Manage Clickthrough Reports /_layouts/ReportServer/ModelClickThrough.aspx?list={ListId}&ID={ItemId}0x0
0x4
FileType
smdl
352
Manage Model Item Security /_layouts/ReportServer/ModelItemSecurity.aspx?list={ListId}&ID={ItemId}0x0
0x2000000
FileType
smdl
353
Regenerate Model
/_layouts/ReportServer/GenerateModel.aspx?list={ListId}&ID={ItemId}0x0
0x4
FileType
smdl
354
Manage Data Sources
/_layouts/ReportServer/DataSourceList.aspx?list={ListId}&ID={ItemId}0x0
0x20
FileType
smdl
351
Load in Report Builder /_layouts/ReportServer/RSAction.aspx?RSAction=ReportBuilderModelContext&list={ListId}&ID={ItemId}0x0
0x2
FileType
smdl
250
Edit in Report Builder /_layouts/images/ReportServer/EditReport.gif /_layouts/ReportServer/RSAction.aspx?RSAction=ReportBuilderReportContext&list={ListId}&ID={ItemId}0x0
0x4
FileType
rdl
250
Edit in Report Builder /_layouts/ReportServer/RSAction.aspx?RSAction=ReportBuilderDatasetContext&list={ListId}&ID={ItemId}0x0
0x4
FileType
rsd
250
Manage Caching Options /_layouts/ReportServer/DatasetCachingOptions.aspx?list={ListId}&ID={ItemId}0x0
0x4
FileType
rsd
350
Manage Cache Refresh Plans /_layouts/ReportServer/CacheRefreshPlanList.aspx?list={ListId}&ID={ItemId}&IsDataset=true0x0
0x4
FileType
rsd
351
Manage Data Sources
/_layouts/ReportServer/DataSourceList.aspx?list={ListId}&ID={ItemId}0x0
0x20
FileType
rsd
352
View Dependent Items /_layouts/ReportServer/DependentItems.aspx?list={ListId}&ID={ItemId}0x0
0x4
FileType
rsd
353
Compliance Details
javascript:commonShowModalDialog('{SiteUrl}/_layouts/itemexpiration.aspx?ID={ItemId}&List={ListId}', 'center:1;dialogHeight:500px;dialogWidth:500px;resizable:yes;status:no;location:no;menubar:no;help:no', function GotoPageAfterClose(pageid){if(pageid == 'hold') {STSNavigate(unescape(decodeURI('{SiteUrl}'))+'/_layouts/hold.aspx?ID={ItemId}&List={ListId}'); return false;} if(pageid == 'audit') {STSNavigate(unescape(decodeURI('{SiteUrl}'))+'/_layouts/Reporting.aspx?Category=Auditing&backtype=item&ID={ItemId}&List={ListId}'); return false;} if(pageid == 'config') {STSNavigate(unescape(decodeURI('{SiteUrl}'))+'/_layouts/expirationconfig.aspx?ID={ItemId}&List={ListId}'); return false;}}, null); return false;0x0
0x1
ContentType
0x01
898
Document Set Version History javascript:SP.UI.ModalDialog.ShowPopupDialog('{SiteUrl}/_layouts/DocSetVersions.aspx?List={ListId}&ID={ItemId}')0x0
0x0
ContentType
0x0120D520
330
Send To other location javascript:GoToPage('{SiteUrl}/_layouts/docsetsend.aspx?List={ListId}&ID={ItemId}')0x0
0x0
ContentType
0x0120D520
350
About Psychiatrist.com | Internet Policy | Privacy Policy | Privacy Glossary | Terms of Use | Contact Us | PPP COVID-19 StatementBrowse by Topic
Anxiolytics
Attention-Deficit/Hyperactivity Disorder Autism Spectrum DisordersBipolar Disorder
Body Dysmorphic DisorderCancer
Cardiology
Catatonia
Child and Adolescent PsychiatryCognition
Comorbidity
Complementary and Alternative MedicineConduct Disorders
Cost/Economics
COVID-19
Cross-Cultural PsychiatryDelirium
Delivery of Care
Dementia
Depression
Dermatology
Diagnostic Tools
Eating Disorders
Education
Electroconvulsive TherapyEncephalitis
End-of-Life/Palliative CareEpidemiology
Epilepsy
Factitious Disorder
Fibromyalgia
Forensics
Functional ImpairmentGastroenterology
Genetics
Geriatric PsychiatryHeadache
Health Services
Hepatitis
Integrated Care
Journal of Clinical PsychiatryMedical Conditions
Metabolic Disorders
Migraine
Mood Disorders
Mood Lability
Movement Disorders
Multiple Sclerosis
Neuroimaging
Neuroleptic Malignant SyndromeNeurology
Neuropsychiatric Disorders Obsessive-Compulsive and Related DisordersPain
Panic Disorder
Parkinson Disease
Pathological Gambling Patient/Physician Communication Personality DisordersPhobic Disorders
Posttraumatic Stress Disorder Premenstrual Dysphoric DisorderPrimary Care
Primary Care Companion for CNS DisordersPsychiatry
Psychopharmacology
Psychotherapy
Psychotic Disorders
Pulmonary Disease
Renal Disease
Research Methods and Statistics Restless Legs SyndromeRheumatology
Schizophrenia/Schizoaffective Disorders Seasonal Affective DisorderSedatives
Seizure
Sexual Dysfunction
Side Effects
Sleep
Smoking
Somatoform DisordersStimulants
Stroke
Substance Use DisordersSuicide
Tardive Dyskinesia
Trauma
Traumatic Brain Injury Treatment Resistance Veterans and Military IssuesViolence/Aggression
Weight
Women’s Mental HealthDid you know?
Late-life depression is associated with lower quality of life, functional decline, and all-cause mortality.Find out more
BLOG
PSYCHIATRIST.COM
Keyword?Go
Home | JCP Weekly | Archive| Authors |
Reviewers
RECENT ARTICLES
Original Research
Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2) Ewa Wajs, Leah Aluisio, Richard Holder, Ella J. Daly, Rosanne Lane, Pilar Lim, Joyce E. George, Randall L. Morrison, Gerard Sanacora, Allan H. Young, Siegfried Kasper, Ahmad Hatim Sulaiman, Cheng-Ta Li, Jong-Woo Paik, Husseini Manji, David Hough, Jennifer Grunfeld, Hong Jin Jeon, Samuel T. Wilkinson, Wayne C. Drevets, and Jaskaran B. Singh J Clin Psychiatry 2020;81(3):19m12891Original Research
Machine Learning Algorithms in Suicide Prevention: Clinician Interpretations as Barriers to Implementation Lily A. Brown, Kathy Benhamou, Alexis M. May, Wenting Mu, and RichardBerk
J Clin Psychiatry 2020;81(3):19m12970Original Research
Efficacy and Safety of Guanfacine Extended-Release in the Treatment of Attention-Deficit/Hyperactivity Disorder in Adults: Results of a Randomized, Double-Blind, Placebo-Controlled Study Akira Iwanami, Kazuhiko Saito, Masakazu Fujiwara, Daiki Okutsu, andHironobu Ichikawa
J Clin Psychiatry 2020;81(3):19m12979 COVID-19: A WORLDWIDE CRISIS Perspectives on the COVID-19 Pandemic and Individuals With SeriousMental Illness
Ann K. Shinn and Mark Viron J Clin Psychiatry 2020;81(3):20com13412 See COVID-19 coverage Home | PCC Weekly | Archive | Authors | ReviewersRECENT ARTICLES
Original Research
Feasibility Study of Stress Management and Resiliency Training (SMART) in Patients With Major Depressive Disorder Ashok Seshadri, Matthew M. Clark, Simon Kung, Matthew Fuller-Tyszkiewicz, Amit Sood, Kristina C. Dammen, Jose A. Rico, Susannah J. Tye, Jane McGillivray, and Mark A. Frye Prim Care Companion CNS Disord 2020;22(3):19m02556Original Research
Antidepressant Prescribing in England: Patterns and Costs Adrian H. Heald, Mike Stedman, Mark Davies, Mark Livingston, David Taylor, and Roger Gadsby Prim Care Companion CNS Disord 2020;22(2):19m02552Original Research
Prevalence and Associated Factors of Depression Among Diabetic Outpatients in Ethiopia Mohammedamin Hajure Jarso and Defaru Desalegn Likasa Prim Care Companion CNS Disord 2020;22(2):19m02479Home | All CME
| MyCME
RECENT ACTIVITIES
Brief Report | Earn 0.50 Credit (Published 04/29/2020, Expires 04/30/2022) Patient-Centered Psychopharmacology and Psychosocial Interventions: Treatment Selection and Shared Decision-Making to Enhance Chances forRecovery
John Lauriello
Webcast | Earn 1.75 Credits (Published 04/03/2020, Expires 04/30/2022) Identifying and Treating Insomnia in Patients Living with Alzheimer’s DiseaseAvidan and Burke
Brief Report | Earn 1.00 Credit (Published 03/31/2020, Expires 03/31/2022) Current Treatment Options and Emerging Agents for Schizophrenia Christoph U. Correll Brief Report | Earn 1.00 Credit (Published 03/31/2020, Expires 03/31/2022) Using Patient-Centered Assessment in Schizophrenia Care: Defining Recovery and Discussing Concerns and Preferences Christoph U. Correll Brief Report | Earn 0.50 Credit (Published 03/10/2020, Expires 03/31/2022) Prevalence and Impact of Relapse in Patients With SchizophreniaJohn Lauriello
Brief Report | Earn 0.50 Credit (Published 03/09/2020, Expires 03/31/2022) How Can Measurement-Based Care Help Improve Treatment Outcomes for Major Depressive Disorder in Primary Care?Madhukar H. Trivedi
Brief Report | Earn 0.50 Credit (Published 03/09/2020, Expires 03/31/2022) Major Depressive Disorder in Primary Care: Strategies forIdentification
Madhukar H. Trivedi
JCP CME | Earn 1.00 Credit (Published 02/18/2020, Expires 04/30/2022) Revisiting Tardive Dyskinesia: Focusing on the Basics of Identification and TreatmentCitrome and Saklad
JCP CME | Earn 1.00 Credit (Published 01/28/2020, Expires 02/28/2022) Early Recognition and Treatment of Tardive Dyskinesia in Patients With Mood Disorders and SchizophreniaMcEvoy and Kremens
Brief Report | Earn 0.50 Credit (Published 01/23/2020, Expires 01/31/2022) Medication Options and Clinical Strategies for Treating TardiveDyskinesia
Leslie L. Citrome
Brief Report | Earn 0.50 Credit (Published 12/26/2019, Expires 12/31/2021) Identifying Tardive Dyskinesia: Risk Factors, Functional Impact, andDiagnostic Tools
Stephen R. Saklad
Brief Report | Earn 0.50 Credit (Published 12/24/2019, Expires 12/31/2021) Strategies for Shifting From Acute to Maintenance Treatment forBipolar I Disorder
Trisha Suppes
Brief Report | Earn 1.00 Credit (Published 12/12/2019, Expires 12/31/2021) Effective Treatment Strategies for Motor and Nonmotor Symptoms ofParkinson Disease
Stuart H. Isaacson
Brief Report | Earn 0.50 Credit (Published 12/09/2019, Expires 12/31/2021) Early Recognition and Diagnosis of Parkinson Disease and OngoingAssessments
Stuart H. Isaacson
Brief Report | Earn 0.50 Credit (Published 12/09/2019, Expires 12/31/2021) Evidence-Based Treatment Targets, Selection, and Strategies for Acute Manic and Mixed Episodes of Bipolar I DisorderTrisha Suppes
JCP CME | Earn 1.00 Credit (Published 12/03/2019, Expires 12/31/2021) Current and Emerging Solutions to Challenges in the Evaluation and Management of Alzheimer’s DiseaseAtri et al
Brief Report | Earn 0.50 Credit (Published 11/25/2019, Expires 11/30/2021) Treatment Strategies for Tardive DyskinesiaDaniel E. Kremens
Brief Report | Earn 0.50 Credit (Published 11/19/2019, Expires 11/30/2021) Earlier Diagnosis of Tardive DyskinesiaDaniel E. Kremens
Brief Report | Earn 0.50 Credit (Published 11/14/2019, Expires 11/30/2021) FDA-Approved Medications to Treat Tardive DyskinesiaJoseph P. McEvoy
Browse by TopicAnxiolyticsAttention-Deficit/Hyperactivity DisorderAutism Spectrum DisordersBipolar DisorderBody Dysmorphic DisorderCancerCardiologyCatatoniaChild and Adolescent PsychiatryCognitionComorbidityComplementary and Alternative MedicineConduct DisordersCost/EconomicsCOVID-19Cross-Cultural PsychiatryDeliriumDelivery of CareDementiaDepressionDermatologyDiagnostic ToolsEating DisordersEducationElectroconvulsive TherapyEncephalitisEnd-of-Life/Palliative CareEpidemiologyEpilepsyFactitious DisorderFibromyalgiaForensicsFunctional ImpairmentGastroenterologyGeneticsGeriatric PsychiatryHeadacheHealth ServicesHepatitisIntegrated CareJournal of Clinical PsychiatryMedical ConditionsMetabolic DisordersMigraineMood DisordersMood LabilityMovement DisordersMultiple SclerosisNeuroimagingNeuroleptic Malignant SyndromeNeurologyNeuropsychiatric DisordersObsessive-Compulsive and Related DisordersPainPanic DisorderParkinson DiseasePathological GamblingPatient/Physician CommunicationPersonality DisordersPhobic DisordersPosttraumatic Stress DisorderPremenstrual Dysphoric DisorderPrimary CarePrimary CareCompanion for CNS
DisordersPsychiatryPsychopharmacologyPsychotherapyPsychotic DisordersPulmonary DiseaseRenal DiseaseResearch Methods and StatisticsRestless Legs SyndromeRheumatologySchizophrenia/Schizoaffective DisordersSeasonal Affective DisorderSedativesSeizureSexual DysfunctionSide EffectsSleepSmokingSomatoform DisordersStimulantsStrokeSubstance Use DisordersSuicideTardive DyskinesiaTraumaTraumatic Brain InjuryTreatment ResistanceVeterans and Military IssuesViolence/AggressionWeightWomen’s Mental HealthINFORMATION LINKS
Terms of Use
| Privacy Policy
| Information
for Authors (JCP)
| Information
for Authors (PCC) | Reprints and Permissions | CNS Job Market | Information for Advertisers| Media
Relations
| Machine-Readable
JCP Archive | PPP COVID-19Statement
HELP
Contact us
| Unsubscribe
from Elerts | Customer Service| FAQ
| About JCP
| About PCC | AboutPsychiatrist.com
OUR FAMILY OF SITES
Psychiatrist.com | The Journal of Clinical Psychiatry | The Primary Care Companion | The CME Institute| Strong Veterans
Copyright 2020
Physicians Postgraduate Press, Inc. Lifelong Learning for Clinicians JCP ISSN: Online 1555-2101, Print 0160-6689 PCC ISSN: Online 2155-7780, Print 2155-7772 MedFair.com US Patent No. 6847940×
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0